Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease.
Saved in:
| Title: | Pimavanserin, a 5HT |
|---|---|
| Authors: | Yuede CM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Wallace CE; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Davis TA; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Gardiner WD; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Hettinger JC; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Edwards HM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Hendrix RD; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Doherty BM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Yuede KM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA., Burstein ES; ACADIA Pharmaceuticals Inc, San Diego, CA, USA., Cirrito JR; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.; Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.; Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA. |
| Source: | Journal of neurochemistry [J Neurochem] 2021 Mar; Vol. 156 (5), pp. 658-673. Date of Electronic Publication: 2021 Jan 10. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley on behalf of the International Society for Neurochemistry Country of Publication: England NLM ID: 2985190R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-4159 (Electronic) Linking ISSN: 00223042 NLM ISO Abbreviation: J Neurochem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-4159 |
|---|---|
| DOI: | 10.1111/jnc.15260 |
